“Combined therapies including immune checkpoint inhibitors or CAR-T and simultaneous provision of low-abundant bacteria synthesizing specific metabolites as an adjunctive agent may be therapeutically useful.” Akkermansia and Bifidobacterium massiliensis and their selective metabolites such as pentanoate may be used as microbial biotherapeutics,” says Dr Alexander Visekruna of the Institute for Medical Microbiology and Hospital Hygiene at Philipps-University Marburg. “Collectively, these results suggest that low-abundant commensal bacterial species such as M. This reprogramming intends to elevate production of molecules such as CD25, IFN-γ and TNF-α, enhancing the anti-tumour activity of CTLs and CAR T cells in mouse melanoma and pancreatic cancer models. This enzyme is responsible for the removal of the acetyl group from histone proteins on DNA, making the DNA less accessible to transcription factors.
Published in Nature Communications, the study sets out to show pentanoate and butyrate enhance anti-tumour activity of CTLs and CAR-T cells through metabolic and epigenetic reprograming.īy treating CTLs and CAR T cells with pentanoate and butyrate in vitro the team from the Philipps-University Marburg, Germany, and Universitätsklinikum Würzburg, Germany, demonstrates an increase in the function of mTOR as a metabolic sensor as well as inhibit activity of histone deacetylase. “This demonstrates not only the importance of Live Biotherapeutics as a new modality poised to revolutionise the treatment of a wide range of cancers, but also the power of our MicroRx platform to continue making significant discoveries and advances in this field.” Pentanoate and butyrate “Using the MicroRx platform we have now shown we have the potential to improve the efficacies of cell therapies such as CAR-T. Imke Mulder, Research Director, 4D pharma “Our existing clinical oncology programs, such as the study of MRx0518 and Keytruda in refractory patients, have shown the important role our live biotherapeutics have to play in the fight against cancer in combination with immunotherapies,” says Dr. The LBP MRx1299, which consists of the bacterium Megasphaera massiliensis and its short chain fatty acid (SCFA) metabolite pentanoate and butyrate, may boost cytotoxic activity of T-lymphocytes (CTL).Īdditionally, MRx1299 was also found to induce production of effector molecules in CTLs as well as in chimeric antigen receptor (CAR-T) cells, resulting in increased anti-tumour reactivity and improved therapeutic outcome. The gut-brain axis: Psychobiotic opportunity in 25 countries.Uncovering white spaces – Probiotics for a smooth menopause transition.Uncovering White Spaces – Probiotics for Pets.POSTbiotics – New Tools in Microbiome Modulation.After the pandemic: Business lessons and insights from 25 probiotic supplement e-markets.
0 kommentar(er)
